Life Sciences Rise In Value Despite Venture Capital Dropoff

Law360, New York (September 11, 2012, 9:18 PM EDT) -- Valuations for life science companies have moved upward this year despite a falloff in venture capital investment, according to Fenwick & West LLP's survey of venture capital financings for 186 U.S.-based life sciences companies.

The firm's First Half 2012 Life Science Venture Capital Survey found that up rounds — a round of funding in which the company's share price has increased since its prior financing round — outpaced down rounds 53 to 19 percent during the first half of 2012. The numbers are an improvement over...
To view the full article, register now.